FinTrust Capital Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

FinTrust Capital Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-165	Closed	-$8K	–	1310
2021 Q4	$8K	Sell	165 -12	-7%	-$622	﹤0.01%	961
2021 Q3	$10K	Hold	177	–	–	﹤0.01%	924
2021 Q2	$8K	Hold	177	–	–	﹤0.01%	982
2021 Q1	$7K	Hold	177	–	–	﹤0.01%	979
2020 Q4	$8K	Hold	177	–	–	﹤0.01%	907
2020 Q3	$8	Buy	177 +140	+378%	+$6.12K	﹤0.01%	873
2020 Q2	$2K	Sell	37 -52	-58%	-$2.59K	﹤0.01%	976
2020 Q1	$4K	Hold	89	–	–	﹤0.01%	930
2019 Q4	$5K	Hold	89	–	–	﹤0.01%	876
2019 Q3	$5K	Buy	89 +7	+9%	+$394	﹤0.01%	894
2019 Q2	$5K	Hold	82	–	–	﹤0.01%	857
2019 Q1	$4K	Sell	82 -369	-82%	-$16.4K	﹤0.01%	1005
2018 Q4	$18K	Buy	+451	New	+$23.2K	0.01%	631

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

FinTrust Capital Advisors's EGRX Position: Q1 2022 in Review

FinTrust Capital Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 165 shares — an estimated $8K sold.

FinTrust Capital Advisors first reported a position in EGRX in Q4 2018 and held it in 13 quarters. The position peaked at $18K in Q4 2018. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

FinTrust Capital Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
FinTrust Capital Advisors sold 165 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $8K.
FinTrust Capital Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2018 and held it in 13 quarters.
FinTrust Capital Advisors's Eagle Pharmaceuticals, Inc. position peaked at $18K in Q4 2018.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on FinTrust Capital Advisors's 13F filing for Q1 2022, filed 3 May 2022.